Study funded by Sanofi.

Download Poster (743.62 KB)

Publication
  • ISTH •
  • 24 June, 2025 •
  • •

Long-term observational joint health study in patients initiating efanesoctocog alfa: baseline data

Jonathan C. Roberts, Larissa Bornikova, Eric Grabowski, Amit Soni, Jennifer Dumont, Charlotte Sensinger, Nicole Tsao

Available materials

Poster
Publication
  • ISTH •
  • 24 June, 2025 •
  • •

Major Surgical Outcomes with Efanesoctocog Alfa: 4 Years’ Experience in the XTEND Clinical Program

Liane Khoo, Robert Klamroth, Annette von Drygalski, Sandrine Meunier, Davide Matino, Umer Khan, Elena Santagostino, Lara Mamikonian, Linda Bystrická, Graham Neill, Flora Peyvandi

Available materials

Oral Presentation
Publication
  • ISTH •
  • 24 June, 2025 •
  • •

Monitoring Joint Health in Hemophilia Patients in Spain: Updated Analysis of the JOINt US Project

María Teresa Álvarez Román, Hortensia de la Corte Rodríguez, César Ricardo Román Banks, María Victoria Aznar, Raquel Bellini, Olga Benitez Hidalgo, Rubén Berrueco Moreno, Santiago Bonanad, Francisco Cholbi, Nuria Fernández Mosteirín, Nino Haya Guaita, Francisco López Jaime, Ángel Martín Fuentes, Santiago Andrés Muñoz, Leire Ortiz Fernández, María Ángeles Peiró Garrigues, Jean Claude Perrot, María Rosario Prieto Bonilla, Manuel Rodríguez López

Available materials

Poster
Publication
  • ISTH •
  • 24 June, 2025 •
  • •

Analysis of Baseline Influences on Platelet Response to Avatrombopag (AVA) from a Phase 3b Multicenter, Randomized, Double-Blind, Placebo (PBO)-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of AVA for the Treatment of Pediatric Pati

Rachael F. Grace, Göksel Leblebisatan, Yesim Aydinok, Şule Ünal, John Grainger, Amanda Grimes, Michele Lambert, Jessica Zhang, Brian D. Jamieson, Michael Vredenburg , Scott Kolodny

Available materials

Poster
Publication
  • WFH CCS •
  • 24 April, 2025 •
  • •

A plain language summary of the association between joint health and patient reported quality of life outcomes using data from the efanesoctocog alfa Phase 3 clinical trial in adults and adolescents with severe haemophilia A

Christoph Königs, Doris Quon, Cedric Hermans, Emilie Gerard, Nana Kragh, Jérôme Msihid, Duygu Bozkaya, Linda Bystrická, Cecile LeCamus, Elena Santagostino, Annemieke Willemze, Annette von Drygalski

Available materials

Oral Presentation
Publication
  • WFH CCS •
  • 23 April, 2025 •
  • •

Plain language summary of two-year results of weekly efanesoctocog alfa treatment in children with severe haemophilia A: Interim analysis of the XTEND-ed phase 3 study

Lynn Malec, Beatrice Nolan, Anthony KC Chan, Manuela Albisetti, Sheng-Chieh Chou, Bulent Zulfikar, Mindy Simpson, Liqi Feng, Helena Palmborg, Graham Neill, Lydia Abad-Franch, Sriya Gunawardena, Karin Fijnvandraat

Available materials

Poster
Publication
  • WFH CCS •
  • 23 April, 2025 •
  • •

Efanesoctocog alfa for the perioperative management of dental surgery in participants with severe hemophilia A: 4 years of experience during the XTEND clinical program

Pratima Chowdary, Lynn Malec, Sophie Susen, Stephanie P’ng, Flora Peyvandi, Lara Mamikonian, Elena Santagostino, Graham Neill, Umer Khan, Linda Bystrická, Ming-Ching Shen

Available materials

Oral Presentation
Symposium
  • WFH CCS •
  • 23 April, 2025 •
  • •

Advancing Haemophilia A Care With New Levels of Protection

Pratima Chowdary, Cedric Hermans, Maissaa Janbain

Available materials

Slides
Sign up for alerts